Objective Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with
substantial patient and population burdens. A number of comorbid health problems occur in …

Background Atopic dermatitis (AD) is associated with psychologic distress. However,
previous studies found conflicting results about whether AD is associated with increased …

Importance Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective
and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic …

Background The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in
the United States population is not well established. Objective To elucidate the patient …

Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …

Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-
selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as …

The implementation of treatment guidelines for atopic dermatitis is challenging, in part
because of different guidance documents being used by different groups of specialists and …

Importance Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-
13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis …

Background The relationship between atopic dermatitis (AD), anxiety and depression in the
US adult population is not well established. Objectives To determine the relationship of AD …

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated
with a high skin‐related health burden, typically starting in childhood and often persisting …